How long does it take to improve HbA1c is one of the most common questions following a diabetes diagnosis or an elevated blood test result. HbA1c — glycated haemoglobin — reflects average blood glucose over the preceding two to three months, meaning meaningful improvements typically take at least this long to show in a retest. Whether you are making dietary changes, increasing physical activity, or starting new medication, understanding the timeline and the factors that influence it can help you set realistic goals and work effectively with your GP or diabetes care team.

What Is HbA1c and Why Does It Matter?

HbA1c measures glycated haemoglobin to reflect average blood glucose over 10–12 weeks; NICE defines 48 mmol/mol or above as diagnostic of type 2 diabetes, with persistently elevated levels linked to serious complications including cardiovascular disease and retinopathy.

Have any more questions about this? Message our pharmaceutical team to get more info →

HbA1c — formally known as glycated haemoglobin — is a blood test that reflects your average blood glucose levels over the preceding two to three months. When glucose circulates in the bloodstream, it binds to haemoglobin (the protein inside red blood cells that carries oxygen). The higher your blood glucose over time, the more glycated haemoglobin is formed. Because red blood cells live for approximately 10–12 weeks, the HbA1c result gives clinicians a reliable window into longer-term glucose control, rather than a single snapshot.

In the UK, HbA1c is measured in millimoles per mole (mmol/mol). According to NICE guidelines (NG28):

• Below 42 mmol/mol is considered normal

• 42–47 mmol/mol indicates prediabetes (non-diabetic hyperglycaemia)

• 48 mmol/mol or above is used to diagnose type 2 diabetes in most clinical contexts

Importantly, in the absence of symptoms of hyperglycaemia, a diagnosis of diabetes based on HbA1c generally requires confirmation on a second sample. A single raised result is usually sufficient only when classic symptoms (such as thirst, polyuria, and unexplained weight loss) are present.

For people already diagnosed with type 2 diabetes, NICE recommends an HbA1c target of 48 mmol/mol (6.5%) for those managed by lifestyle alone or with a single medicine not associated with hypoglycaemia. A higher target of 53 mmol/mol (7.0%) is generally recommended for people taking medicines that carry a risk of hypoglycaemia, such as insulin or a sulfonylurea. Individual targets may be adjusted further depending on age, frailty, comorbidities, and patient preference.

HbA1c matters because persistently elevated levels are strongly associated with the development of serious long-term complications, including cardiovascular disease, diabetic retinopathy, nephropathy, and peripheral neuropathy. Reducing HbA1c — even modestly — has been shown in landmark trials such as the UKPDS to significantly reduce the risk of these complications.

When HbA1c may be unreliable or unsuitable HbA1c can give misleading results in certain situations, and alternative markers (such as fructosamine) may be used instead. HbA1c is generally not recommended or may be unreliable in:

• Pregnancy (including gestational diabetes assessment)

• Children and young people

• Suspected type 1 diabetes or rapid-onset diabetes

• Conditions affecting red blood cell turnover, such as iron deficiency anaemia, haemolytic anaemia, or haemoglobinopathies

• Recent blood transfusion

• Advanced chronic kidney disease (CKD)

• Acute illness

Your GP or diabetes care team will advise on the most appropriate test if any of these circumstances apply.

How Long Does It Take to See HbA1c Improvements?

Meaningful HbA1c improvements typically take two to three months to appear in a blood test, reflecting the lifespan of red blood cells; NICE recommends retesting every three to six months when treatment or lifestyle changes are made.

One of the most common questions people ask after a diabetes diagnosis or a high HbA1c result is how quickly they can expect to see improvement. The honest answer is that meaningful changes typically take two to three months to become apparent in a blood test, and this is directly linked to the biology of red blood cells. Because HbA1c reflects an average over the lifespan of red blood cells (roughly 10–12 weeks), any improvements you make today will not be fully captured in a test taken next week. Self-monitoring of blood glucose or continuous glucose monitoring (CGM) may show earlier changes in day-to-day glucose levels, but these do not replace HbA1c as a measure of longer-term control.

In practice, NICE (NG28) recommends retesting HbA1c every three to six months when adjusting treatment or making significant lifestyle changes, and every six months once levels are stable on unchanged therapy. More frequent testing may be appropriate if clinically indicated. This monitoring schedule allows enough time for genuine trends to emerge without over-interpreting short-term fluctuations.

For people making substantial dietary and lifestyle changes, studies suggest that measurable reductions in HbA1c can begin to appear within eight to twelve weeks. For those starting new medications, the timeframe varies by drug class but improvements are generally detectable within the same three-month window. More dramatic reductions — for example, following a very low-calorie diet (as demonstrated in the DiRECT trial) or bariatric surgery — can occur more rapidly, sometimes within four to eight weeks, though these represent more intensive interventions.

It is important to set realistic expectations. A reduction of 5–10 mmol/mol over three to six months is considered clinically meaningful and is achievable for many people through combined lifestyle and pharmacological approaches. Larger reductions are possible but depend heavily on starting HbA1c, individual response, and adherence to changes.

Factors That Affect How Quickly HbA1c Changes

Starting HbA1c level, duration of diabetes, medication adherence, concurrent illness, and conditions affecting red blood cell turnover all influence how quickly and significantly HbA1c responds to intervention.

Several variables influence how rapidly — and how significantly — HbA1c responds to intervention. Understanding these factors can help set realistic goals and guide clinical decision-making.

Starting HbA1c level is one of the strongest predictors of how much improvement is possible. Someone with an HbA1c of 85 mmol/mol has considerably more room for improvement than someone at 52 mmol/mol, and may see larger absolute reductions in the same timeframe.

Duration of diabetes also plays a role. In the earlier stages of type 2 diabetes, the pancreas retains more insulin-secreting capacity, meaning lifestyle changes and medications tend to have a more pronounced effect. As the condition progresses, beta-cell function declines, and achieving target HbA1c may require more complex treatment regimens.

Other important factors include:

• Adherence to dietary changes and physical activity — consistency is key; sporadic efforts produce limited results

• Medication adherence — missing doses significantly blunts the effectiveness of glucose-lowering medicines

• Concurrent illness or stress — both physical illness and psychological stress can raise blood glucose through hormonal mechanisms (particularly cortisol and adrenaline), temporarily worsening HbA1c

• Medicines that raise blood glucose — systemic corticosteroids (steroids) are a common cause of raised glucose and can transiently worsen HbA1c; other medicines may also affect glucose control. Inform your diabetes team if you are prescribed a new medicine

• Anaemia or haemoglobin variants — conditions affecting red blood cell turnover (such as iron deficiency anaemia, haemolytic anaemia, or haemoglobinopathies) can produce falsely low or high HbA1c readings. In these situations, clinicians may use alternative markers such as fructosamine

• Kidney disease — chronic kidney disease can affect HbA1c accuracy and also limits the use of certain medications

Your diabetes care team will consider all of these factors when interpreting your results and planning the most appropriate management strategy.

Lifestyle Changes That Can Help Lower HbA1c

Dietary changes, physical activity, and weight loss are the cornerstones of HbA1c management; the NHS Type 2 Diabetes Path to Remission Programme uses a very low-calorie diet (around 800 kcal/day) and has achieved remission in a significant proportion of participants.

Lifestyle modification remains the cornerstone of HbA1c management, particularly in the early stages of type 2 diabetes or prediabetes. Evidence consistently shows that structured changes to diet and physical activity can produce clinically significant reductions in HbA1c — in some cases comparable to the effect of a single glucose-lowering medication.

Dietary changes are among the most impactful interventions. Reducing intake of refined carbohydrates and added sugars helps limit post-meal glucose spikes. Approaches with good evidence include:

• Low-carbohydrate diets — associated with meaningful HbA1c reductions in a number of studies, though the magnitude varies between individuals

• Mediterranean-style diets — rich in vegetables, legumes, wholegrains, fish, and healthy fats; supported by NICE (NG28) as a dietary pattern beneficial for cardiovascular and metabolic health

• Very low-calorie diets (around 800 kcal/day) — the basis of the NHS Type 2 Diabetes Path to Remission Programme, which has demonstrated HbA1c reductions sufficient to achieve remission in a significant proportion of participants. Very low-calorie diets should only be undertaken within a clinician-supervised programme. If you are taking insulin, a sulfonylurea, or other medicines that can cause hypoglycaemia, your doses will need careful adjustment — do not start a very low-calorie diet without first discussing this with your diabetes care team

Physical activity improves insulin sensitivity and helps muscles use glucose more efficiently. The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week, alongside muscle-strengthening (resistance) exercise on two or more days. Even modest increases in daily movement — such as brisk walking — can produce measurable improvements in glucose control.

Weight loss is particularly powerful. Losing 5–10% of body weight can reduce HbA1c meaningfully, and losses of 15 kg or more (as achieved in the DiRECT trial, published in The Lancet) have been associated with type 2 diabetes remission in a substantial proportion of participants.

Structured diabetes education — such as the DESMOND or X-PERT programmes — can help you understand your condition and make sustainable changes. Ask your GP or diabetes nurse about programmes available in your area.

Smoking cessation and keeping alcohol within recommended limits (no more than 14 units per week, spread across the week, with alcohol-free days) also support better metabolic control and overall health. NHS Stop Smoking services can provide support with quitting.

Medicines Used to Improve HbA1c Levels in the UK

Metformin is the standard first-line treatment for type 2 diabetes in the UK, with SGLT-2 inhibitors and GLP-1 receptor agonists recommended by NICE for people with cardiovascular disease, heart failure, or chronic kidney disease; HbA1c should be rechecked three months after any medication change.

When lifestyle changes alone are insufficient to achieve HbA1c targets, NICE guidelines (NG28) recommend the addition of glucose-lowering medication. The choice of medicine depends on individual factors including kidney function, cardiovascular risk, heart failure, weight, and tolerability.

Metformin remains the standard first-line pharmacological treatment for most people with type 2 diabetes in the UK. It works primarily by reducing hepatic glucose production and improving insulin sensitivity. It is generally well tolerated, inexpensive, and can reduce HbA1c by approximately 10–15 mmol/mol at therapeutic doses. Gastrointestinal side effects (nausea, diarrhoea) are common initially but often improve with gradual dose titration or use of modified-release formulations. Metformin should be avoided if eGFR is below 30 ml/min/1.73m² and the dose reviewed at lower eGFR thresholds. Long-term metformin use has been associated with reduced vitamin B12 absorption; the MHRA advises that B12 monitoring should be considered in patients at risk or with relevant symptoms.

If HbA1c remains above target despite metformin, NICE recommends considering additional agents. The choice is increasingly guided by comorbidities:

• SGLT-2 inhibitors (e.g., dapagliflozin, empagliflozin) — reduce glucose by promoting urinary glucose excretion; also offer cardiovascular and renal protective benefits. NICE recommends considering these earlier in treatment for people with established atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease, sometimes alongside or instead of metformin. Important safety information: SGLT-2 inhibitors carry a risk of diabetic ketoacidosis (DKA), including euglycaemic DKA (where blood glucose may not be markedly elevated). They also increase the risk of genital and urinary tract infections. These medicines should be temporarily stopped during acute illness, surgery, or prolonged fasting ('sick-day rules') — your care team will advise you on this

• GLP-1 receptor agonists (e.g., semaglutide, liraglutide) — stimulate insulin secretion in a glucose-dependent manner and suppress appetite; associated with significant weight loss and HbA1c reductions. Use should align with NICE criteria, which consider factors such as inadequate control on other agents, BMI, and weight-related comorbidities

• DPP-4 inhibitors (e.g., sitagliptin) — generally well tolerated with modest HbA1c-lowering effects

• Sulfonylureas (e.g., gliclazide) — effective but carry a risk of hypoglycaemia and weight gain

• Insulin therapy — used when oral agents are insufficient, particularly in type 1 diabetes or advanced type 2 diabetes

All medicines are prescribed and monitored by a GP or diabetes specialist, and HbA1c should be rechecked approximately three months after any medication change to assess response.

Reporting side effects: If you experience unexpected or concerning side effects from any diabetes medicine, report these to your prescriber. You can also report suspected adverse reactions directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app. The MHRA and EMA regularly review the safety profiles of these medicines.

When to Speak to Your GP or Diabetes Care Team

Contact your GP or diabetes nurse if HbA1c remains above target after three to six months, or if you experience symptoms of DKA, hypoglycaemia, or a new foot problem; seek emergency care via 999 or NHS 111 for life-threatening complications.

Knowing when to seek professional advice is an important part of managing diabetes safely. While many people can make meaningful progress with lifestyle changes and prescribed medication, there are circumstances where prompt contact with your GP or diabetes care team is essential.

Contact your GP or diabetes nurse if:

• Your HbA1c remains above your agreed target after three to six months of treatment or lifestyle changes

• You are experiencing symptoms of poorly controlled blood glucose, such as persistent thirst, frequent urination, unexplained fatigue, or blurred vision

• You are having recurrent episodes of hypoglycaemia (low blood sugar), particularly if you are on insulin or a sulfonylurea

• You have started a new medication and are experiencing side effects that are affecting your daily life or that concern you

• You develop a new foot problem, such as a sore, blister, ulcer, or signs of infection — diabetic foot problems can deteriorate quickly and should not be left untreated

• You are pregnant or planning a pregnancy — tight glucose control is especially important during this period, and targets differ from those in the general population

Seek urgent medical attention — call NHS 111 or 999 as appropriate — if you develop:

• Symptoms of diabetic ketoacidosis (DKA): vomiting, abdominal pain, rapid or laboured breathing, fruity-smelling breath, or confusion. DKA can occur in people taking SGLT-2 inhibitors even when blood glucose is not markedly elevated (euglycaemic DKA)

• Symptoms of hyperosmolar hyperglycaemic state (HHS): extreme thirst, severe dehydration, confusion or drowsiness, and very high blood glucose — this is a serious emergency more commonly seen in type 2 diabetes

• A severe hypoglycaemic episode that does not resolve with oral glucose

• A serious foot problem such as a spreading infection, new ulcer, or signs of acute Charcot foot — call 999 or go to your nearest emergency department if you are concerned

Call 999 for any life-threatening emergency.

Regular structured reviews are a key part of NHS diabetes care. Most people with type 2 diabetes should receive an annual review covering HbA1c, blood pressure, cholesterol, kidney function, foot examination, and eye screening. Eye screening is organised separately through the NHS Diabetic Eye Screening Programme. These appointments are an opportunity to reassess targets, adjust treatment, and address any concerns. If you feel your diabetes is not well managed or that your treatment plan needs reviewing, do not wait for your next scheduled appointment — contact your practice proactively. Early intervention consistently leads to better long-term outcomes.

Frequently Asked Questions